ライフサイエンスコーパス: axilla

1 response (no invasive carcinoma in breast or axilla).

2 uestions about optimal local therapy for the axilla.

3 ared according to response in the breast and axilla.

4 invasive alternative to SLNB for staging the axilla.

5 ; P = .0029) significantly raised pCR breast/axilla.

6 vulva, perineum, inguinal creases, and left axilla.

7 ntation of compounds secreted from the human axilla.

8 uce the regrowth of lymphatic network in the axilla.

9 iations in arm lymphatic drainage within the axilla.

10 e with a thickened cortex in the ipsilateral axilla.

11 on the management of the clinically negative axilla.

12 ally effective in treating the node-positive axilla.

13 biopsy for patients with clinically negative axilla.

14 Corynebacterium spp. were predominant in the axilla.

15 depicted unsuspected metastases outside the axilla.

16 All located SLNs were in the axilla.

17 % of patients with a histologically negative axilla.

18 nizing squamous cell metastasis in the right axilla.

19 y lower doses and surgical management of the axilla.

20 ied sentinel nodes, six had a tumor-negative axilla.

21 ntense myocardial activity that obscured the axilla.

22 umber of excised LNs were calculated for the axilla (3 levels), neck (</=3 or >/=4 dissected levels),

23 S rRNA copies of bacteria was present in the axilla (4.44 +/- 0.18 log(10) copies/mul [mean +/- stand

24 ested a total of 555 specimens: 103 from the axilla, 93 from blood, 92 from conjunctiva, 54 from fore

25 ess or paresthesias of the medial arm and/or axilla after surgery; in 125 (82%) of these, the problem

26 iotherapy to the residual breast but not the axilla; all were prescribed tamoxifen for 5 years.

27 In a patient with a clinically negative axilla, ALND is performed primarily for staging purposes

28 as predictive for prevalence of tumor in the axilla and for PET sensitivity.

29 esses, nodules, and draining fistulas in the axilla and groin of young adults.

30 ) is a newly developed method of staging the axilla and has the potential to avoid an ALND in lymph n

31 n and avoidance of arm lymphatics within the axilla and its use may reduce lymphedema.

32 with the highest percent composition in the axilla and the lowest in the forearm.

33 98% of C-ECSNs had somatic fields on chest, axilla and upper back areas.

34 le number of SLNs was found (2.5 vs. 2.8 per axilla), and the concordance between isotope and dye in

35 rate, 29% microscopic foci in breast and/or axilla, and 57% gross tumor.

36 overall: 99.3% for the groin, 95.3% for the axilla, and 84.5% for the neck basins.

37 The breast, axilla, and sternum were illuminated with NIR light and

38 luded the forehead, nostrils, buccal mucosa, axilla, antecubital fossa, groin, and toe webs with sepa

39 Somatic receptive fields on chest, axilla, arm and upper back areas were found for 77/95 (8

40 the SLNs and allows immediate staging of the axilla, avoiding the need to coordinate diagnostic servi

41 the treatment unit; specimens taken from the axilla, blood, conjunctiva, forehead, mouth, rectum, and

42 s states that the pathological status of the axilla can be accurately predicted by determining the st

43 he advent of sentinel lymph node biopsy, the axilla can be accurately staged in patients with T1-T3,

44 This method allows axilla-conserving surgery in patients responding well to

45 rld and has revolutionised management of the axilla during the past decade.

46 e application of SLN surgery for staging the axilla following chemotherapy for women who initially ha

47 of 18 patients, 22%; P > .05) and breast and axilla (four of 30 patients, 13% v four of 18 patients,

48 "typical" European HS, mainly involving the axilla, groin, and, in women, the inframammary region.

49 nal-beam radiation therapy to the breast and axilla >3 years before enrollment and ten healthy women

50 Nine (20%) of 44 axilla had histologically confirmed lymph node involveme

51 The sentinel nodes were outside the axilla in 8 percent of cases and outside of level 1 node

52 al basis and rationale for management of the axilla in clinical trials of omission of cancer surgery

53 PURPOSE OF REVIEW: The management of the axilla in early breast cancer remains controversial.

54 nts (23%; 95% CI, 12% to 37%) and breast and axilla in eight patients (17%; 95% CI, 8% to 30%).

55 rrently the standard of care for staging the axilla in patients with clinical T1-T2, N0 breast cancer

56 The surgical approach of the axilla in patients with early-stage breast cancer has wi

57 surgical methods for accurately staging the axilla in patients with early-stage breast cancer have b

58 uestioned, and appropriate management of the axilla in such patients is unknown.

59 9mTc-HIG began to flow under the cuff to the axilla, indicating Ppump>or=Pcuff.

60 res from nasal and extranasal sites (throat, axilla, inguinal, perirectal, and chronic wound if prese

61 Failure to identify an SLN to the axilla intraoperatively occurred in 26 of 466 patients (

62 If treatment of the axilla is indicated in patients with breast cancer who h

63 When accurate preoperative staging of the axilla is needed in patients with newly diagnosed invasi

64 with a clinically and radiologically normal axilla is sentinel lymph node biopsy with a radioisotope

65 se sites included bone, liver, contralateral axilla, lung, chest wall, pelvis, and the subpectoral, s

66 The ratio of unaffected to affected axilla lymphatic velocity (1.24 +/- 0.18) was significan

67 ging using this modified oblique view of the axilla (MOVA) started immediately after peritumoral inje

68 ks (n = 6), knees (n = 3), calf (n = 1), and axilla (n = 1).

69 ed samples from the nasal cavity, mouth, and axilla of a human subject could be successfully determin

70 juvant chemotherapy can completely clear the axilla of microscopic disease before surgery, and occult

71 Rates of pCR in the breast only and the axilla only exhibited similar differences across tumor s

72 from healthy controls were obtained from the axilla only.

73 specimens were obtained from lesional skin (axilla or groin) and nonlesional skin.

74 In patients with pCR in breast and axilla, PFS and OS rates were 100% (95% CI, inestimable)

75 a for operative procedures of the breast and axilla, reduces postoperative nausea and vomiting, and p

76 When propulsion in the breast and axilla regions was present, the mean apparent velocities

77 decreased oral intake, the presence of a dry axilla supports the diagnosis of hypovolemia (positive l

78 agmatic-field radiotherapy not including the axilla than among those who were exposed to mantle-field

79 and prevents the recurrence of cancer in the axilla, there is a significant incidence of long-term si

80 h early breast cancer and a clinically clear axilla treated by conservative surgery, postoperative ra

81 Lymph transit time from hand to axilla, ttransit, was 9.6+/-7.2 min (mean+/-s.d.) (veloc

82 The metastatic distribution in the axilla was determined in patients with occult nodal dise

83 or more intense foci of tracer uptake in the axilla was highly predictive of axillary metastasis (78%

84 High-dose FDG PET of the axilla was successfully performed in 50 patients (age ra

85 Surgery, including evaluation of the axilla, was done within 6 weeks of completion of neoadju

86 Rates of pCR in both the breast and axilla were 38.2% in triple-negative, 45.4% in HER2-posi

87 thin this study population, PET scans of the axilla were interpreted with sufficient sensitivity for

88 ed definitive radiotherapy to the breast and axilla, whereas patients with residual disease underwent

89 portant issues relating to management of the axilla, which includes not only the indications and tech

90 uent identification of arm lymphatics in the axilla, which would have been transected during routine

91 N) biopsy was adopted for the staging of the axilla with the assumption that it would reduce the risk

92 de biopsy was adopted for the staging of the axilla with the assumption that it would reduce the risk

93 e agents on pCR breast (ypT0/is), pCR breast/axilla (ypT0/isN0), treatment delivery, and toxicities w